Drug interactions
Erythromycin base + Indacaterol-glycopyrronium
Severity: Moderate
Erythromycin base and Indacaterol-glycopyrronium: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erythromycin inhibits CYP3A4 and P-glycoprotein and can raise systemic indacaterol exposure modestly. Both drugs can also affect cardiac repolarisation, so beta-agonist effects such as tachycardia, tremor and QT prolongation may be more likely.
What this interaction means in plain words
Erythromycin base and Indacaterol-glycopyrronium can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Inhibition of CYP3A4 and P-gp reduces indacaterol clearance, with possible additive QT effects from erythromycin and beta-agonism.
What to do
No dose change is generally needed at the standard inhaled dose, but monitor for palpitations, tremor and hypokalaemia. Consider an ECG in patients with QT risk factors or other QT-prolonging drugs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erythromycin base and Indacaterol-glycopyrronium, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Frequently asked questions
Can I take Erythromycin base with Indacaterol-glycopyrronium?
MediHelp rates the interaction as moderate. Erythromycin base and Indacaterol-glycopyrronium can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erythromycin inhibits CYP3A4 and P-glycoprotein and can raise systemic indacaterol exposure modestly. Both drugs can also affect cardiac repolarisation, so beta-agonist effects such as tachycardia, tremor and QT prolongation may be more likely.
How serious is the interaction between Erythromycin base and Indacaterol-glycopyrronium?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is generally needed at the standard inhaled dose, but monitor for palpitations, tremor and hypokalaemia. Consider an ECG in patients with QT risk factors or other QT-prolonging drugs.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
